What Happened?

A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most countries, sparking renewed optimism amid ongoing trade talks. The major stock indices rose as investors, growing impatient of seemingly irrational tariff actions, welcomed the pause as a sign of a more measured path forward.

However, Trump was quick to note that China was not part of the pause. Instead, he prepared to raise tariffs on Chinese goods to 125% after China announced retaliatory tariffs on US imports. This tough stance on China stood in sharp contrast to the softer tone toward others. In a week marked by growing uncertainty, this news eased some of the pressure. The questions remain whether we are out of the woods and can sustain the rally or not.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, following stocks were impacted:

Genomics & Sequencing company PacBio (NASDAQ:PACB) jumped 24.7%. Is now the time to buy PacBio? Access our full analysis report here, it’s free. Healthcare Technology for Patients company Hims & Hers Health (NYSE:HIMS) jumped 14.9%. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free. Genomics & Sequencing company 10x Genomics (NASDAQ:TXG) jumped 20.4%. Is now the time to buy 10x Genomics? Access our full analysis report here, it’s free. Therapeutics company Moderna (NASDAQ:MRNA) jumped 10.4%. Is now the time to buy Moderna? Access our full analysis report here, it’s free.

Zooming In On PacBio (PACB)

PacBio’s shares are extremely volatile and have had 99 moves greater than 5% over the last year. But moves this big are rare even for PacBio and indicate this news significantly impacted the market’s perception of the business.

PacBio is down 19% since the beginning of the year, and at $1.46 per share, it is trading 59.6% below its 52-week high of $3.61 from April 2024. Investors who bought $1,000 worth of PacBio’s shares 5 years ago would now be looking at an investment worth $502.59.

Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

View Comments